



- About Dementia +
- Caring ... +
- News +
- Literature +
- Community +
- Resources +
- Your Doctor +

News

News

18/09/2008 - Findings from E.L. Tobinick and co-authors broaden understanding of Alzheimer disease

2008 SEP 22 - -- According to recent research published in the journal BMC Neurology , "Recent clinical studies point to rapid and sustained clinical, cognitive, and behavioral improvement in both Alzheimer's disease and ...

Pain & Central Nervous System Week via NewsEdge :

). This outcome is concordant with recent basic science studies suggesting that TNF-alpha functions in vivo as a gliotransmitter that regulates synaptic function in the brain."

"We hypothesized that perispinal etanercept had the potential to improve verbal function in Alzheimer's disease, so we included several standardized measures of verbal ability to evaluate language skills in a clinical trial of perispinal etanercept for Alzheimer's disease. This was a prospective, single-center, open-label, pilot study, in which 12 patients with mild-to-severe Alzheimer's disease were administered etanercept, 25 - 50 mg, weekly by perispinal administration for six months. Two additional case studies are presented. Two-tailed, paired t-tests were conducted comparing baseline performance to 6-month performance on all neuropsychological measures. Test batteries included the California Verbal Learning Test-Second Edition, Adult Version; Logical Memory I and II(WMS-LM-II) from the Wechsler Memory Scale-Abbreviated; the Comprehensive Trail Making Test (TMT); Boston Naming Test; and letter(FAS) and category verbal fluency. All measures revealed a significant effect except for the Boston Naming Test and the TMT-4, with WMS-LM-II being marginally significant at $p = .05$. The FAS test for letter fluency was most highly significant with a $p < 0.0007$. In addition, rapid improvement in verbal fluency and aphasia in two patients with dementia, beginning minutes after perispinal etanercept administration, is documented. In combination with the previously reported results of perispinal etanercept in Alzheimer's disease and primary progressive aphasia, these results further argue that larger scale studies of this therapeutic intervention, including Phase 3 trials, are warranted in dementias," wrote E.L. Tobinick and colleagues.

The researchers concluded: "In addition, these results may provide insight into the basic pathophysiologic mechanisms underlying Alzheimer's disease and related forms of dementia, and suggest the existence of novel, rapidly reversible, TNF-mediated pathophysiologic mechanisms in Alzheimer's disease which are worthy of further investigation."

, 2008;8():27).

For additional information, contact E.L. Tobinick, Private Med Group Inc., Neurology Research Institute, Los Angeles, CA, USA.

is: Biomedical Central Ltd., Current Science Group, Middlesex House, 34-42 Cleveland St., London W1T 4LB, England.

<>

<< Copyright ©2008 Pain & Central Nervous System Week via NewsRx.com >>

Sign up for our newsletter

Your email address:

Mental Health via RSS



Learn more



We subscribe to the HONcode principles. **Verify here.**